The perioperative management of new direct oral anticoagulants: a question without answers

• Published in: Thrombosis and haemostasis Vol. 110; no. 3; p. 515
• Main Authors: Ferrandis, R, Castillo, J, de Andrés, J, Gomar, C, Gómez-Luque, A, Hidalgo, F, Llau, J V, Sierra, P, Torres, L M
• Format: Journal Article
• Language: English
• Published: Germany 01.09.2013
• Subjects: Administration, Oral; Aged; Anesthesiology; Anticoagulants - administration & dosage; Anticoagulants - chemistry; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles - administration & dosage; beta-Alanine - administration & dosage; beta-Alanine - analogs & derivatives; Dabigatran; Female; Hemorrhage - prevention & control; Hemostasis; Heparin, Low-Molecular-Weight - therapeutic use; Humans; Male; Morpholines - therapeutic use; Patient Safety; Perioperative Period; Pyrazoles - therapeutic use; Pyridones - therapeutic use; Rivaroxaban; Thiophenes - therapeutic use; Thromboembolism - prevention & control

New direct oral anticoagulant agents (DOAC) are currently licensed for thromboprophylaxis after hip and knee arthroplasty and for long-term prevention of thromboembolic events in non-valvular atrial fibrillation as well as treatment and secondary prophylaxis of venous thromboembolism. Some other med...